Stroke research clinical trials

Here you will find links to the currently open clinical trials which are ran within Stroke Research, our older closed Stroke Research trials and any upcoming trials which are going through the process of set up.

These pages will be updated whenever we have started a new trial or are in the early stages of set up.

Below is a link to a file which shows our current recruitment in all of our open trials. Further information on trials can be found in the open trials page of this website.

Here you will find a list of all of the current Open Clinical Trials that we are running within the Stroke Research Team. Should you wish to find out any more pieces of information about the trials, please send an email and we will answer your query.

Trial short title	ATTEST-2
Trial long title	Alteplase-Tenecteplase trial evaluation for stroke thrombolysis
Trial outcome	To compare the safety and efficacy of Tenecteplase with Alteplase for thrombolysis in acute ischaemic stroke
Chief investigator	Prof. Keith Muir
Principle investigator	Dr. Ahamad Hassan
Start date	12/12/2016
Project type	Non-Commercial

Trial short title	BRAINS
Trial long title	British Repository of DNA in Stroke
Trial outcome	To establish a Caucasian and South Asian Stroke DNA repository
Chief investigator	Dr. Pankaj Sharma
Principle investigator	Dr. Ahamad Hassan
Start date	02/04/2007
Project type	Non-Commercial

Trial short title	DNA LACUNAR-2
Trial long title	Genetic Risk Factors for Cerebral Small Vessel Disease
Trial outcome	Can genetic risk factors underlying MRI-defined lacunar stroke be identified using the traditional GWAS approach, and can we increase the ability to detect novel genetic variants by leveraging disease heterogeneity?
Chief investigator	Prof. Hugh Markus
Principle investigator	Dr. Ahamad Hassan
Start date	11/08/2016
Project type	Non-Commercial

Trial short title	ECST-2
Trial long title	The 2nd European Carotid Surgery Trial
Trial outcome	An international randomised trial investigating the optimal treatment of patients with symptomatic or asymptomatic moderate or severe carotid stenosis at low or intermediate risk of future stroke.
Chief investigator	Prof. Martin Brown
Principle investigator	Dr. Marc Randall
Start date	23/03/2012
Project type	Non-Commercial

Trial short title	FAMILIAL
Trial long title	A UK Familial Cerebral Small Vessel Disease Study
Trial outcome	To perform a longitudinal prospective study of patients with familial SVD, both due to known genes causing monogenic SVD, and also cases with Mendelian inheritance in which the underlying genes have not yet been identified.
Chief investigator	Prof. Hugh Markus
Principle investigator	Dr. Ahamad Hassan
Start date	24/06/2016
Project type	Non-Commercial

Trial short title	RIGHT-2
Trial long title	Rapid Intervention With Glyceryl Trinitrate in Hypertensive Stroke Trial-2
Trial outcome	Assessment of safety and efficacy of transdermal glyceryl trinitrate, a nitric oxide donor, and of the feasibility of a multicentre ambulance-based stroke trial
Chief investigator	Prof. Philip Bath
Principle investigator	Dr. Ahamad Hassan
Start date	25/09/2015
Project type	Non-Commercial

Trial short title	RESTART
Trial long title	Restart or Stop Antithrombotics Ramdomised Trial
Trial outcome	Testing whether a policy of starting antiplatelet drugs (one or more of aspirin, clopidogrel, or dipyridamole, chosen at investigator’s discretion) results in a beneficial net reduction of all serious vascular events over two years compared with a policy of avoiding antiplatelet drugs.
Chief investigator	Prof. Rustam Al-Shahi Salman
Principle investigator	Dr. Ahamad Hassan
Start date	01/05/2013
Project type	Non-Commercial

Trial short title	XILO-FIST
Trial long title	Xanthine Oxidase Inhibition for Improvement of Long-term Outcomes Following Ischaemic Stroke and Transient Ischaemic Attack
Trial outcome	To evaluate the effect of allopurinol 300 mg twice daily on white matter hyper-intensity (WMH) progression, left ventricular hypertrophy (LVH) and arterial blood pressure (BP) after ischaemic stroke.
Chief investigator	Dr. Jesse Dawson
Principle investigator	Dr. Ahamad Hassan
Start date	18/05/2015
Project type	Non-Commercial

Here you will find a list of all of the current Closed Clinical Trials that we are running within the Stroke Research Team. Should you wish to find out any more pieces of information about the trials, please send an email and we will answer your query.

Trial short title	CROMIS-2
Trial long title	Microbleeds and genetic risk factors to predict the risk of intracranial haemorrhage in tatients treated with anticoagulation following cardioembolic stroke due to atrial fibrillation
Trial outcome	To develop a successful predictive model for ICH risk after best practice oral anticoagulation for AF will help to determine whether genetic or CMB screening should be used in clinical practice and future trials. New genetic, clinical and radiological risk factors associated with anticoagulant-related ICH will be identified.
Chief investigator	Dr. David Werring
Principle investigator	Dr. John Bamford
Start date	27/02/2012
End date	31/10/2017
Project type	Non-Commercial

Trial short title	ENCHANTED
Trial long title	Enhanced control of hypertension and thrombolysis stroke study
Trial outcome	This study is an international, multicentre, prospective, fixed-time point (optional) randomisation for two arms ([A] ‘dose of rtPA’ and [B] ‘level of BP control’), open, blinded endpoint (PROBE), controlled trial that will involve 4800 patients (3300 for arm [A] and 2304 for arm [B] with overlap of approximately 800 patients) with acute ischaemic stroke recruited from over 100+ Clinical Centres from Australia, Asia, Europe and South America.
Chief investigator	Prof. Craig Anderson
Principle investigator	Dr. Ahamad Hassan
Start date	08/06/2012
End date	31/08/2018
Project type	Non-Commercial

Trial short title	EXTRAS
Trial long title	A trial to evaluate an extended rehabilitation service for stroke patients
Trial outcome	The EXTRAS trial aims to determine the clinical and cost effectiveness of an extended stroke rehabilitation service. Stroke patients and carers who agree to participate in the trial are randomly allocated to either receive a new extended stroke rehabilitation service or to continue with usual NHS care. The effectiveness of the new extended rehabilitation service will be evaluated by comparing the health of patients and carers who received the new service with those who received usual NHS care.
Chief investigator	Prof. Helen Rodgers
Principle investigator	Dr. John Bamford
Start date	05/11/2012
End date	30/06/2015
Project type	Non-Commercial

Trial short title	FOCUS
Trial long title	Fluoxetine or control under supervision
Trial outcome	Does the routine administration of fluoxetine (20mg od) for 6 months after an acute stroke improve patients’ functional outcome?
Chief investigator	Prof. Martin Dennis and Prof. Gillian Mead
Principle investigator	Dr. John Bamford
Start date	01/04/2012
End date	01/06/2016
Project type	Non-Commercial

Trial short title	PISTE
Trial long title	Pragmatic Ischaemic Stroke Thrombectomy Evaluation
Trial outcome	To determine if endovascular thrombectomy in addition to IV thrombolysis improves the proportion of patients with favourable functional 3 month outcome (defined by modified Rankin 0-2) in patients with acute ischaemic stroke due to occlusion of the middle cerebral or intracranial internal carotid artery
Chief investigator	Prof. Keith Muir
Principle investigator	Dr. John Bamford
Start date	02/04/2013
End date	28/04/2015
Project type	Non-Commercial

Trial short title	PRESERVE
Trial long title	How intensively should we treat blood pressure in established cerebral small vessel disease
Trial outcome	To determine whether a strategy of intensive, verses standard, treatment of BP in hypertensive individuals with SVD and leukoaraiosis is associated with reduced cognitive decline
Chief investigator	Prof. Hugh Markus
Principle investigator	Dr. Ahamad Hassan
Start date	14/10/2011
End date	02/11/2015
Project type	Non-Commercial

Trial short title	STRO 3595 NAVIGATE ESUS
Trial long title	Multicenter, randomized, double-blind, double-dummy, active-comparator, event-driven, superiority phase III study of secondary prevention of stroke and prevention of systemic embolism in patients with a recent Embolic Stroke of Undetermined Source (ESUS), comparing rivaroxaban 15 mg once daily with aspirin 100 mg (NAVIGATE ESUS)
Trial outcome	The NAVIGATE ESUS research study is seeking a safe and more effective alternative to aspirin treatment to prevent another stroke in patients who already suffered a stroke of uncertain cause. “ESUS” stands for Embolic Stroke of Undetermined Source.
Chief investigator	Robert G. Hart M.D and Stuart J. Connolly M.D
Principle investigator	Dr. Vasileios Papavasileiou
Start date	23/12/2014
End date	15/02/2018
Project type	Commercial

Trial short title	TARDIS
Trial long title	Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke
Trial outcome	Safety and efficacy of intensive versus guideline antiplatelet therapy in high risk patients with recent ischaemic stroke or transient ischaemic attack: a randomised controlled trial
Chief investigator	Prof. Philip Bath
Principle investigator	Dr. John Bamford
Start date	07/04/2009
End date	13/04/2016
Project type	Non-Commercial

Trial short title	TICH-2
Trial long title	Tranexamic acid for hyperacute primary intracerebral haemorrhage
Trial outcome	To assess whether tranexamic acid is safe and reduces death and dependency after hyperactute (within 8 hours of onset) primary intracerebral haemorrhage
Chief investigator	Dr. Nikola Sprigg
Principle investigator	Dr. Sameer Limaye
Start date	01/03/2013
End date	31/07/2017
Project type	Non-Commercial

Trial short title	VIST
Trial long title	Vertebral artery ischaemic stenting trial
Trial outcome	A multicentre randomised controlled open prospective clinical trial comparing vertebral stenting with best medical treatment
Chief investigator	Prof. Hugh Markus
Principle investigator	Dr. Ahamad Hassan
Start date	23/10/2008
End date	09/02/2015
Project type	Non-Commercial

Please click on any of the following links below to be taken straight to the clinical trial information.

Trial short title	R4VaD
Trial long title	Rates, Risks and Routes to Reduce Vasular Dementia
Trial outcome	To determine rates of cognitive impairment and dementia to at least two years after stroke, across a wide range of patients, stroke severities and subtypes, stratified by patient-related (age, premorbid and pre-stroke cognition, socioeconomic status, vascular risk factors, lifestyle) and stroke related (severity, ischaemic, haemorrhagic, lacunar v non-lacunar, imaging findings) factors. We will also perform mechanistic substudies (detailed neuroimaging, vascular function, high-sensitivity inflammatory markers and genetic analysis) and establish a well-characterised population consented for recontact for future studies.
Chief investigator	Prof. Joanna Wardlaw
Principle investigator	Dr. Ahamad Hassan
Estimated start date	Early 2019
Project type	Non-Commercial
More information	https://www.dementiasplatform.uk/

Trial short title	SIGNUM
Trial long title	Stroke Investigation Network – Understanding Mechanisms
Trial outcome	SIGNUM is an observational study that will recruit patients from stroke services including TIA clinics, HASU’s, ASU’s, rehabilitation facilities, GP’s and any other service that looks after such patients. We will also include patients who are at risk of stroke for example those with arterio-venous malformations, cavernomas or extra cranial vessel abnormalities. The main focus of which is on collecting genetic and biomarker data linked to data recorded as part a patient’s routine care, using the paper or electronic health record, however numerous projects are expected to emerge from the network. This model will enable the research to be embedded into routine clinical care, with the aim of being cost effective and time efficient. The longitudinal component of collecting functional outcomes will be embedded into routine follow up clinics, and where necessary supplemented by linking with GP records and/or postal/telephone/web based or routine and research clinic contact. Links to electronic health databases (HES, SSNAP, and CPRD, MINAP and similar data / disease registries) and routine clinical follow ups within clinical stroke services themselves will facilitate collection of hard endpoints of morbidity and mortality, disease specific endpoints and endpoints that may represent adverse reactions to medications used for the treatment and/ or prevention of stroke.
Chief investigator	Dr. Reecha Sofat
Principle investigator	Dr. Ahamad Hassan
Estimated start date	Early 2019
Project type	Non-Commercial
More Information	https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/determinants-of-prognosis-in-stroke/

Telephone

Support our charity

Cookie settings